Hostname: page-component-848d4c4894-8bljj Total loading time: 0 Render date: 2024-06-28T01:46:51.690Z Has data issue: false hasContentIssue false

A Case Report of Asenapine Augmentation of Clozapine in Resistant Bipolar Type I.

Published online by Cambridge University Press:  15 April 2020

M. Preve
Affiliation:
Psychiatric Clinic, Sociopsychiatric Organization, Mendrisio, Switzerland
F. Valente
Affiliation:
Psychiatric Clinic, Sociopsychiatric Organization, Mendrisio, Switzerland
A. Zitolo
Affiliation:
Psychiatric Clinic, Sociopsychiatric Organization, Mendrisio, Switzerland
R. Colombo
Affiliation:
Psychiatric Clinic, Sociopsychiatric Organization, Mendrisio, Switzerland
R. Traber
Affiliation:
Psychiatric Clinic, Sociopsychiatric Organization, Mendrisio, Switzerland

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction and purpose of the study

Asenapine is an atypical antipsychotic indicated for the treatment of schizophrenia and of the manic or mixed episodes in bipolar I disorder [1]. The different therapeutics option like mood stabilizers and atypical antipsychotics are used to better treat the single episode but also to stabilize manic/depressive cyclicity [2]. The aim of this case report is to underline a possible augmentation of asenapine to clozapine.

Method

'Mrs. T.P.', is a caucasian woman aged 45 suffering from bipolar disorder type I followed by mixed depressive phases with subsequent short free period. The patient was treated with different typical and atypical antipsychotics, combined with mood stabilizers, with a partial response. With lithium 900 mg/day, valproate 1500 mg/day and clozapine 250 mg/day showed a partial improvement and remission of the symptoms. To that point we introduced asenapine 20 mg/day with rapid clinical improvement without major side effects. After 1 year the patient is still showing a good affective stability, with an improvemnt of metabolic and without cognitive side effects.

Discussion and conclusions

Our case report underlines the possibility of asenapine augmentation of clozapine in bipolar I disorder therapy resistant manic patients [3]. Asenapine can increase the plasmatic levels of clozapine, exhibits a unique effect and his pharmacodynamic characteristics may mediate its symptom relief in positive, negative and mood symptoms. Further research is warranted to replicate our clinical observation.

Type
Article: 1142
Copyright
Copyright © European Psychiatric Association 2015

References

Szegendi, et al., 2011.Google Scholar
Vieta, Eet al., 2005.Google Scholar
Green, Alet al., 2000.Google Scholar
Submit a response

Comments

No Comments have been published for this article.